X

QualityStocksNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI), Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Partner in Pre-Clinical Trial Application for Psilocybin Extract

Numinus Wellness (TSX.V: NUMI), a mental-health-care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, has joined with Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) to submit an all-natural psilocybin extract to Health Canada for pre-clinical trial approval. Optimi Health is the developer of a vertically integrated functional mushroom brand focused on the health and wellness sector. The submission to Health Canada marks a significant milestone in the development of the extract. The two companies submitted the application through Impact Clinical Trials Accelerator at the University of Calgary; validation studies as well as cultivation, research, and formulation have been conducted at the Health Canada-licensed Numinus lab in British Columbia, Canada. “Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural Psilocybe sources and prepare them for Health Canada submissions and approvals,” said Numinus BioScience general manager and science officer Sharan Sidhu in the press release. “We look forward to continuing our work with Optimi to develop safe, standardized and reproducible products that provide meaningful and accurate clinical trial data.”

To view the full press release, visit https://ibn.fm/jwMHd

About Numinus Wellness Inc.

Numinus Wellness empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model —  including psychedelic production, research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. Numinus is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. For more information about the company, please visit www.Numinus.ca.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Related Post